Stem cell transplant is the replacement of damaged bone marrow cells with healthy cells (stem cells). Stem cells are immature cells produced in the bone marrow that make more stem cells, red blood cells, white blood cells, and platelets.
Although some people experience few problems with a transplant, others may develop complications that may require treatment or hospitalization. Together you can weigh the risks and benefits to decide whether a stem cell transplant is right for you.
The usual doses of chemotherapy drugs can cause serious side effects to quickly dividing tissues such as the bone marrow. A stem cell transplant (SCT) allows doctors to use higher doses of chemotherapy and, sometimes, radiation therapy.
Multiple Myeloma: Stem Cell Transplant for Healthy Blood Multiple Myeloma: Stem Cell Transplant for Healthy Blood SOURCE
Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2009. Stem cell transplant (peripheral blood, bone marrow, and cord blood transplants).
Stem cell transplant (SCT) is the only treatment that can cure chronic myelomonocytic (MY-eh-loh-MAH-noh-SIH-tik) leukemia (CMML). Then the patient receives new, functioning blood-forming stem cells.
Giving chemotherapy to the entire body before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored.
Stem cell transplants can benefit people with a variety of both cancerous (malignant) and noncancerous (nonmalignant) diseases. Doctors then infuse into your body healthy stem cells that previously have been collected from you or a donor.
l. Ten days before the transplant (Day 10), subjects will be admitted to the bone marrow transplant unit and placed in isolation to reduce exposure to infections. Isolation will be continued until adequate numbers of cells are present in the blood to fight infection.
The main types are: Autologous ("Auto") Stem Cell Transplant This type of transplant uses your own stem cells. Most transplants for multiple myeloma and relapsed non-Hodgkin's or Hodgkin lymphoma are autologous.
This is a phase I, dose-escalation study of melphalan and bortezomib followed by a phase II study. Patients receive melphalan intravenously (IV) continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1.